AJAkiva Juroviesky

Akiva Juroviesky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akiva Juroviesky has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Direct Comparison of Two Commonly Used Prenatal Valproate Doses Identifies Different Sex- and Age-Related Neurobehavioral Outcomes Across Development

    by Maria Becker, Denis Gorobets, Boniface Ezenwata Echefu, Akiva Juroviesky, Anna Beylis, Aviv Sela, Asher Ornoy

    Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, direct comparisons between commonly used doses are lacking. We compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-related behavior, sociability, and spontaneous alternation. Early development was largely preserved, although VPA300 delayed cliff aversion acquisition. Total ultrasonic vocalization production was unaffected, while selected call types were altered. Later behavioral effects differed across dose, sex, and age. In males, locomotor activity and center exploration were preserved, sociability was reduced by both VPA doses, and spontaneous alternation was reduced by VPA300 at postnatal day 70 (PND70). In females, locomotor activity was reduced by VPA600 at PND30 and VPA300 at PND70, center exploration was reduced by VPA600, and sociability was reduced by VPA300 at both ages and VPA600 at PND70. VPA600 was also associated with greater embryonic mortality. These findings show that the two VPA doses were associated with differing patterns of developmental and behavioral outcomes, without a consistent increase in severity at the higher dose.

  • Open Access

    Direct Comparison of Two Commonly Used Prenatal Valproate Doses Reveals Non-Linear and Sex-Dependent Neurobehavioral Outcomes Across Development

    by Maria Becker, Denis Gorobets, Boniface Echefu, Akiva Juroviesky, Anna Beylis, Aviv Sela, Asher Ornoy

    Valproic acid (VPA) is a widely used anticonvulsant and mood stabilizer and a known teratogen associated with neural tube defects and neurodevelopmental disorders, including autism spectrum disorder (ASD). Prenatal VPA exposure is widely used to model ASD-like behaviors in rodents; however, most studies employ a single dose, and direct comparisons between commonly used regimens are lacking. We therefore compared two widely used VPA doses (300 and 600 mg/kg) administered to pregnant mice on embryonic day 12.5 (E12.5). Male and female offspring were evaluated longitudinally for early neurological development, ultrasonic vocalizations, locomotor activity, anxiety-like behavior, sociability, and working memory. Prenatal VPA exposure produced non-linear, dose- and sex-dependent effects. Early neurodevelopment was largely preserved, with only mild and transient delays that were most evident after 300 mg/kg. In contrast, later behavioral alterations differed according to dose, sex, age, and behavioral measure. Sociability deficits were stable across doses in males but became more pronounced with age in females, whereas working memory impairment predominated after 600 mg/kg during adolescence and after 300 mg/kg in adulthood. These findings demonstrate that increasing prenatal VPA dose does not simply increase behavioral severity but produces distinct neurodevelopmental trajectories that depend on dose, sex, and developmental stage.